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  42 
ALL acute lymphoblastic leukemia 
AML acute myeloid leukemia 
BM bone marrow 
CNS Central nervous system 
CR complete remission 
CsA ciclosporin A 
DRM disease related mortality 
EFS event-free survival 
GvHD Graft versus host disease 
HSCT hematopoietic stem cell transplantation 
MDS myelodysplastic syndrome 
MFD matched family donor 
MPS myeloproliferative syndrome 
OS overall survival 
SGOT serum glutamic oxaloacetic transaminase 
TBI total body irradiation 
TRM treatment related mortality 
UD unrelated donor 
VOD Veno-occlusive disease 
Abstract 43 
Background: Standard myeloablative conditioning regimens for children with 44 
hematological malignancies undergoing allogeneic HSCT are based mainly on total 45 
body irradiation or busulfan.  Their serious short and long-term side effects warranted 46 
the exploration of less toxic alternatives. Treosulfan is increasingly used for adults 47 
and children before HSCT due to its potent immunosuppressive and cytotoxic effects 48 
combined with low organ toxicity.  49 
Procedure: To further investigate the role of treosulfan conditioning in children, the 50 
EBMT Paediatric diseases working party performed a retrospective analysis of 193 51 
children with hematological malignancies (ALL n=71, AML n=47, MDS/MPS n=40, 52 
other leukemia/lymphoma n=25) undergoing allogeneic HSCT following treosulfan 53 
between January 2005 and July 2010.  54 
Results: Early regimen-related toxicity was low and mainly gastrointestinal. Veno-55 
occlusive disease and neurological toxicity were rare. There was no association of 56 
toxicity with type of disease or treosulfan dose. High-grade early toxicity was not 57 
higher in infants or patients undergoing second or later transplantation. Treatment 58 
related mortality was low at 14%. Three-year event-free survival was 45±4% and not 59 
significantly influenced by number of HSCT, however it appeared to be significantly 60 
better for infants (p=0,022). When compared to treosulfan plus fludarabine, the 61 
combination of treosulfan, fludarabine and an alkylator (either thiotepa or melphalan) 62 
resulted in significantly better overall survival (OS, p=0.048) and a trend towards 63 
better EFS. 64 
Conclusions:  Treosulfan based conditioning is a safe and effective approach for 65 
children with hematological malignancies, including and importantly for infants and 66 
those patients undergoing second or later transplantation.   67 
  68 
Introduction 69 
During recent decades, outcome for pediatric patients with various malignant 70 
hematological disorders following chemotherapy alone  has improved markedly; 71 
indications for allogeneic HSCT have therefore changed and nowadays HSCT is 72 
usually considered when relapse occurs. [1-6] For ALL and AML allogeneic HSCT in 73 
first CR is recommended only if high risk criteria like certain genetic abnormalities or 74 
poor response to induction therapy are met. [1,2] Up-front intensive chemotherapy 75 
leads to a high rate of long-term remission in children with lymphoma, yet allogeneic 76 
HSCT represents an effective rescue therapy for refractory or relapsed cases.[6,7] In 77 
contrast to children with leukemia and lymphoma, primary allogeneic HSCT is 78 
considered to be the therapy of choice for almost all those with MDS and MPS. [8,9] 79 
Current standard conditioning regimens for matched related or unrelated donors for 80 
pediatric patients with hematological malignancies are mostly based on fractionated 81 
TBI or busulfan. [7,9,10] Although both approaches are associated with proven 82 
effective immunosuppressive, myeloablative and anti-malignant activity, high 83 
percentages of acute and late toxicities represent a major disadvantage.[11-14]  84 
Treosulfan (L-treitol-1,4-methanesulfonate) is a prodrug of a bifunctional alkylating 85 
cytotoxic agent and has been initially used as an antineoplastic agent for ovarian 86 
carcinoma. In recent years, it has been increasingly applied to pediatric and adult 87 
patients with hematological malignancies as, and has been shown to be associated 88 
with low risk of organ toxicity and treatment-related mortality combined with effective 89 
immunosuppressive and cytotoxic properties.[15-18]  90 
To investigate whether subgroups of children with leukemia benefit from a treosulfan 91 
containing regimen and to identify risk factors for treatment failure, the EBMT 92 
Paediatric diseases working party conducted a retrospective study on all pediatric 93 
patients registered in the EBMT database between January 2005 and July 2010 who 94 
received treosulfan as part of the conditioning regimen before allogeneic HSCT. 95 
While results of a subgroup of patients with ALL were recently published [19], we 96 
here report an analysis of all 193 pediatric patients with hematological malignancies.  97 
 98 
Patients and methods 99 
Patients 100 
In total, 843 patients up to 18 years of age who underwent HSCT between January 101 
2005 and July 2010 and were registered in the EBMT database were eligible for this 102 
retrospective analysis. Here we present data from a subgroup of 193 patients 103 
diagnosed with malignant haematological disorders undergoing allogeneic HSCT 104 
following treosulfan based conditioning from paediatric transplant centers in 12 105 
countries (Germany, Italy, United Kingdom, Poland, Russia, Netherlands, 106 
Switzerland, Finland, Lithuania, Israel, Austria, Czech Republic).  The study was 107 
conducted in accordance with the EBMT Guidelines for retrospective studies. The 108 
subgroup of 71 patients with ALL included in this analysis has been described in a 109 
recent publication. [19] 110 
Table I shows detailed patient characteristics. Patients were diagnosed with ALL 111 
(n=71), AML (n=57), MDS or MPS (n=40) and other types of leukaemia or lymphoma 112 
(n=25). Median age at HSCT was 9.1 years. Eleven children were below the age of 113 
one year at the time of transplant, seven of whom were diagnosed with ALL. 114 
Conditioning and transplantation 115 
The majority of children were transplanted either without having achieved complete 116 
remission (no CR, 40%) or in >CR1 (39%), for the first time (74%), from an UD (58%) 117 
and with BM as the stem cell source (50%). Reasons for a treosulfan based 118 
conditioning regimen were: second or third HSCT, pre-transplant organ dysfunction 119 
or advanced stage of disease. Treosulfan was combined with different 120 
chemotherapeutic agents, most frequently with fludarabine and thiotepa (33%) or 121 
cyclophosphamide (25%, ± other drug). Dosages for treosulfan were based on 122 
calculated body surface area for all patients, including infants. The most frequent 123 
dose range for treosulfan was between 3x13 and <3x15g/sqm (61%). Six of the 124 
eleven infants received a treosulfan dose of >3x13 g/sqm. The majority of children 125 
received a CsA containing GvHD prophylaxis (80%) which was combined with 126 
methotrexate in 37%. GVHD prophylaxis was comparable between patients 127 
undergoing first or later HSCT and patients in different stages of remission (1. CR, > 128 
1. CR, no CR; data not shown). Patient characteristics were similar between the 129 
different types of diseases with regard to treosulfan dosing range, stem cell source 130 
and number of HSCT (supplementary table I). Main differences were as follows: 131 
patients with other leukemia/lymphoma were older, the percentage of patients not in 132 
CR at transplant was higher in the groups of MDS/MPS and other 133 
leukemia/lymphoma patients were more likely to receive a transplant from a MFD 134 
compared to the other groups. While most patients with ALL or MDS/MPS received 135 
treosulfan in combination with cyclophosphamide, a combination of treosulfan, 136 
fludarabine and melphalan was applied to a higher percentage of patients with AML 137 
compared to other diagnoses (supplementary table I). Combination of conditioning 138 
drugs according to diagnosis is demonstrated in supplementary figure 1: while the 139 
majority of patients who received cyclophosphamide in addition to treosulfan (n=48) 140 
were diagnosed with ALL (n=23, 48%), most patients who received fludarabine and 141 
melphalan (n=25) were diagnosed with AML (n=14, 56%).  142 
Acute and chronic GvHD were graded according to the Seattle criteria. [20] Early 143 
regimen related toxicity up to day +100 was defined and graded using the Short 144 
Name based on the Common Terminology Criteria for Adverse Events v3.0 145 
(CTCAE), available online at: http://ctep.cancer.gov/forms/.  146 
Endpoints and statistics 147 
Outcome was measured as follows: myeloid engraftment (3 consecutive days with an 148 
absolute neutrophil count >0,5x10E/L), graft failure, early regimen-related toxicity up 149 
to day +100, incidence of acute (at day +100) and chronic GvHD (at 1 year), OS, 150 
DRM, TRM, EFS, relapse incidence and  non-relapse mortality at 3 years. For all 151 
endpoints, the time to event interval started at the day of HSCT, and ended at the 152 
day of the respective first event for uncensored or at the day of last follow up for 153 
censored individuals. 154 
Univariate statistical analysis was done in subgroups defined by remission status, 155 
conditioning regimen, number of HSCT and patient age. Kaplan-Meier estimates and 156 
log-rank tests were used to evaluate OS and EFS.[21,22] For OS, deaths from any 157 
cause were considered to be an event. Relapse, progression or death from any 158 
cause were considered as events for EFS. Cumulative incidences of events were 159 
calculated by the method of Fine and Gray for censored data subject to competing 160 
risks, and compared using the Gray test.[23,24] The cumulative incidence of non-161 
relapse mortality was estimated taking into account the competing risk of mortality 162 
after relapse, the cumulative incidence of relapse/progression taking into account the 163 
competing risks of death without relapse and graft failure, the cumulative incidence of 164 
ANC engraftment taking into account the competing risks of lost graft, death without 165 
engraftment and subsequent HSCT, and the cumulative incidence of TRM taking into 166 
account the deaths after relapse and subsequent SCT without treosulfan-based 167 
conditioning. Mantel-Haenszel Chi-Square test and Chi-Square test were used to 168 
compare categorical non time-to event variables: toxicities, acute GvHD and chronic 169 
GvHD. 170 
Multivariate analysis was performed to study the impact of confounding factors on the 171 
defined outcomes. Cox regression was used to model the time to relapse, TRM, EFS 172 
and OS. Acute and chronic GvHD were modelled as time dependent variables when 173 
investigating their effect on outcome; the standard PHREG procedure in SAS was 174 
used for this calculation (observation time was censored at death). Logistic 175 
regression was used to model the rate of acute GvHD of grade 3/4, and the 1 year 176 
rate of chronic GvHD.[21,22,25] Because of the relatively small sample size and 177 
hence low GvHD numbers, treosulfan dose and patient age were included into the 178 
logistic regressions as continuous variables and only a possible linear relationship 179 
with the respective dependent variable was investigated. 180 
The statistical analysis was done with SAS System V9.2 (2008, SAS Institute, Cary, 181 
NC). All p-values below 0.05 were considered to be significant. 182 
 183 
Results 184 
Early regimen related toxicity 185 
Early regimen related toxicity is shown in detail in figure 1. Toxicity ≥ grade 3 186 
occurred as follows: stomatitis 29%, diarrhea 17%, vomiting 11%, respiratory toxicity 187 
12%, elevated bilirubin 11%, elevated SGOT 27%, CNS toxicity 4% and peripheral 188 
neurological  toxicity 3%. Grade 4 toxicity of any kind was observed in less than 10% 189 
of patients besides stomatitis grade 4, which was detected in 12% (diarrhea 8%, 190 
vomiting 6%, respiratory toxicity 7%, elevated bilirubin 6%, elevated SGOT 6%, CNS 191 
toxicity 3%, peripheral neurological toxicity 1%). VOD occurred in 3% of patients. 192 
Occurrence of high-grade toxicity was not significantly different between the different 193 
types of diseases (table II). Patients undergoing second or third HSCT did not 194 
experience higher rate of high-grade early toxicity of any category compared to 195 
patients at first HSCT. High-grade early toxicity was not higher in infants, liver toxicity 196 
was even significantly more frequent in older children. There was no significant 197 
association between higher treosulfan dose and CTA grade 3 or 4 toxicity. Besides 198 
lower incidence of elevated bilirubin and maximum liver toxicity in patients who 199 
received fludarabine and thiotepa/melphalan in addition to treosulfan and lower 200 
elevated bilirubin in treosulfan + cyclophosphamide patients, there was no significant 201 
association between high-grade toxicity and combination of conditioning drugs (table 202 
II). 203 
Engraftment 204 
Myeloid engraftment was achieved in 185/191 (97%) of patients at a median of 18 205 
days. Six patients died between day +10 and +38 without signs of engraftment, for 206 
the remaining two data on engraftment was not available in the database. 207 
Acute and chronic GvHD 208 
Acute GvHD occurred in 50% (96/191) of patients, GvHD ≥ grade 3 was observed in 209 
12% (23/191). Twenty-four % of patients (39/160) showed signs of chronic GvHD 210 
(extensive GvHD in 15/160, 9%). There was no significant association between 211 
occurrence of acute or chronic GvHD and diagnosis (acute>grade 1 p=0.49, 212 
acute>grade 3 p=0.33, chronic p=0.19, chronic extensive p=0.12). While acute GvHD 213 
of any grade occurred significantly more often in younger children (0-1 year 73%, 1-214 
12 years 54%, >12 years 39%, p=0.047), this difference was not seen for the higher 215 
grades of acute GvHD or for chronic extensive GvHD (>grade 3: 0-1 year 9%, 1-12 216 
years 13%, >12 years 11%, p= 0.84, chronic extensive: 0-1 year 9%, 1-12 years 8%, 217 
>12 years 13%, p=0.60). GvHD occurrence was not significantly influenced by 218 
number of HSCT (acute >grade 1: first HSCT 53%, >first 42%, p=0.17; acute >grade 219 
3: first 14%, >first 6%, p=0.13, chronic extensive: first 11%, >first 5%, p=0.32). 220 
Acute GvHD grade ≥3 occcured in 10/96 (10%) patients who received bone marrow 221 
as stem cell source comparable to 11/71 (15%) following HSCT with peripheral blood 222 
stem cells (p=0.33) while chronic GvHD occurred less frequently with BM (16/85 223 
evaluable patients, 19% vs. 17/54, 31%, p=0.037).    224 
Outcome 225 
Overall and event-free survivals at 3 years for all 193 patients were 54 ± 4% and 45 ± 226 
4%, respectively. Different diagnosis and number of HSCT did not have a significant 227 
effect on EFS or OS (figure 2 A and B; first HSCT: 0.46±0.04 and 0.58±0.04, >first 228 
HSCT: 0.41±0.07 and 0.46±0.07, p=0.32 and 0.17). Status at HSCT tended to 229 
influence outcome with OS and EFS being worse for patients who were not in 230 
remission (EFS figure 2C; OS: CR1 0.65±0.08, >CR1 0.58±0.06, no CR 0.45±0.06, 231 
p=0.097). Infants seemed to have a better outcome (OS 0-1 year 0.91±0.09, 1-12 232 
years 0.51±0.05, >12 years 0.54±0.06, p=0.053) – for EFS this difference was 233 
statistically significant (figure 2D). OS and EFS were not significantly influenced by 234 
treosulfan dose. Regarding different combinations of conditioning agents, addition of 235 
fludarabine alone and the group of other non-alkylating drugs were associated with 236 
significantly worse OS and EFS (figure 2E and F). Addition of an alkylating drug 237 
(thiotepa or melphalan) to fludarabine was associated with significantly better OS and 238 
a tendency for better EFS compared to fludarabine alone (OS 0.55±0.06 vs 239 
0.38±0.08, p=0.048, EFS 0.48±0.05 vs 0.32±0.07, p=0.076). Both groups were 240 
comparable regarding clinical parameters such as year and number of HSCT, 241 
remission status at transplant, stem cell source and donor. Addition of 242 
cyclophosphamide compared to fludarabine and thiotepa or melphalan resulted in 243 
comparable EFS (0.56±0.07 vs. 0.48±0.05, p=0.51). 244 
Treatment related mortality at 3 years was low for the whole group (27/193, 14±2%). 245 
The main cause of death was disease related (DRM at 3 years 54/193, 28±3%). 246 
Neither DRM nor TRM were significantly influenced by diagnosis, number of HSCT, 247 
disease status or treosulfan dose (table III). No infant died of TRM and DRM tended 248 
to be lower than in the other age groups (p=0.15). Accordingly, relapse rate in the 249 
infant group was low (0.09±0.09, 1-12 years 0.45±0.05, >12 years 0.40±0.06, 250 
p=0.093). While TRM was similar between the combinations of conditioning drugs, 251 
DRM was higher when treosulfan was combined with fludarabine alone or with other 252 
non-alkylating drugs (table III).  253 
Multivariate analysis 254 
In a Cox regression analysis of EFS, OS, TRM and relapse, the following risk factors 255 
were included: diagnosis, number of HSCT, remission status, age, treosulfan dose, 256 
conditioning regimen, donor type and stem cell source (table IV).  257 
Undergoing HSCT without having achieved CR was associated with worse OS 258 
(p=0.033) and EFS (p=0.003) and with a higher relapse rate (p=0.003). Patients with 259 
MDS/MPS or with other leukemia/lymphoma had significantly better EFS (p=0.001 260 
and 0.006) with lower relapse rate (p=0.004 both). Infant age was associated with 261 
better EFS as well (p=0.048). Transplantation from a MFD resulted in significantly 262 
better outcome compared to mismatched family donor (OS p=0.002, EFS p=0.047) 263 
with lower TRM (p=0.005) while relapse rate was similar. While HSCT from an 264 
unrelated donor was associated with significantly higher TRM as well (p=0.03), OS 265 
tended to be worse (p=0.06). Combining treosulfan with cyclophosphamide or with 266 
fludarabine and thiotepa or melphalan yielded in tendency a better OS compared to a 267 
combination of treosulfan and fludarabine alone (p=0.06 and 0.09). Number of HSCT, 268 
treosulfan dose, and stem cell source did not significantly influence outcome.  269 
Occurence of neither acute nor chronic GvHD had a statistically significant effect on 270 
EFS or OS. For acute GvHD, however a trend towards better OS and EFS could be 271 
seen (Hazard ratio 0,68 and 0,72, p= 0.13 and 0,15). While acute GvHD was 272 
associated with significantly lower relapse incidence (Hazard ratio 0,71, p=0,009), 273 
occurence of chronic GvHD was associated with a trend to lower relapse (Hazard 274 
ratio 0,78, p=0,19). Acute GvHD did not significantly influence TRM (Hazard ratio 275 
1,46, p=0,38). For chronic GvHD, influence on TRM was not calculated as only 5 276 
patients died of TRM past day +100. All statistical calculations in the multivariate 277 
setting have to be regarded with caution because of the relatively small number of 278 
patients and events. 279 
 280 
Discussion  281 
Serious early and late toxicity from well-established conditioning regimens based on 282 
TBI or busulfan for patients with hematological malignancies demand the search for 283 
alternative regimens. For patients undergoing second or later transplantation and for 284 
infants who are particularly prone to regimen-related toxicity, the requirement for less 285 
toxic conditioning regimens is urgent. During  recent years, treosulfan has been 286 
increasingly used for allogeneic HSCT in pediatric patients with malignant and non-287 
malignant disorders with promising results with respect to toxicity, engraftment, 288 
GvHD and relapse. [26-30] In this retrospective analysis, the EBMT pediatric 289 
diseases working party investigated the toxicity profile and outcome of 193 children 290 
with hematological malignancies who underwent allogeneic HSCT following the use 291 
of treosulfan.  292 
Our cohort reached a high rate of engraftment comparable with that of earlier reports. 293 
[27,28] 294 
Early regimen related toxicity was low and mainly gastrointestinal. In particular, 295 
severe toxicity (grade3) occurred in less than 30% of patients and consisted mainly 296 
of stomatitis and increase of liver enzymes (figure 1). Infants and patients undergoing 297 
a second or later transplantation who are particularly at risk of toxicity did not 298 
experience higher rate of early toxicity. High grade mucosal toxicity was seen in up to 299 
45% of pediatric patients following TBI or busulfan/cyclophosphamide  and in 43% of 300 
patients in a recent pediatric study using a combination of busulfan with 301 
fludarabine.[11,31] This percentage is higher than that observed in our cohort 302 
following treosulfan (29%).  Busulfan has been associated with a substantial risk of 303 
VOD and profound respiratory and neurotoxic side effects.[32-35] Recent studies 304 
have reported a lower incidence of toxicity with therapeutic drug monitoring of iv 305 
busulfan, however this has not been proven in a large cohort of children with 306 
hematological malignancies.[36,37] Pharmocokinetic studies of treosulfan in children 307 
have confirmed a linear relationship between dose and area under the curve.[17] 308 
However, due to considerable inter-patient variability after receiving the same dose, 309 
the significance of therapeutic drug monitoring of treosulfan is not yet clear. [17,38]  310 
 In comparison to busulfan, neurotoxicity in our cohort was rare which can be 311 
explained by the low potential of treosulfan and its active monoepoxide to cross the 312 
blood-brain barrier.[39] To prevent CNS relapse in malignant diseases, treosulfan 313 
should be combined with a CNS-penetrating drug such as thiotepa.  Death due to 314 
pulmonary toxicity was reported in up to 14% of patients following TBI or 315 
busulfan.[33] High grade respiratory toxicity was experienced in only 12 % of patients 316 
in our cohort. Remarkably, respiratory toxicity was not significantly higher in patients 317 
undergoing second or later HSCT although these patients are at high risk of toxic and 318 
infectious lung complications. VOD occurred in only 3% of our patients compared to 319 
rates of up to 22% following busulfan.[34,35]  320 
Our cohort experienced a low rate of TRM (14±2%) which was not significantly 321 
influenced, in univariate and multivariate analysis, by number of HSCT, age or type of 322 
disease (table III and IV). TRM between 25 and 35% for pediatric ALL and lymphoma 323 
patients following TBI-based and between 17 and 25% for busulfan-based 324 
myeloablative conditioning have been reported.[7,12,33,40] For MDS and AML 325 
patients undergoing first HSCT following busulfan, cyclophosphamide and 326 
melphalan, a comparably low rate of TRM (12-14%) was previously observed.[8,35] 327 
Still, TRM rate in our cohort is impressively low as treosulfan was chosen for our 328 
patients based on second or later HSCT and/or pre-existing organ function forbidding 329 
the administration of TBI or busulfan. 330 
TBI as well as busulfan based conditioning regimens have substantial side effects in 331 
infants. [41-43] Treosulfan based conditioning has been shown to be well tolerated in 332 
infants with immunodeficiency disorders and seems to provide sufficient 333 
antineoplastic activity in infant ALL. [29,44,45] Treosulfan is usually administered in a 334 
total dose between 36 and 42 g/sqm for children undergoing Allo-HSCT.[14,15,27,45] 335 
However, for malignant diseases and high-risk infant ALL in particular, concerns were 336 
raised as to whether a total dose of 36 g/sqm would be sufficient to prevent relapse – 337 
but higher doses might result in higher toxicity, especially in infants who are prone to 338 
toxicity.[44,45] In this analysis we showed  that a total dose of >39 g/sqm of 339 
treosulfan was not associated with significantly higher toxicity or TRM. Infants 340 
exhibited low early toxicity without a single case of treatment related death, even 341 
though six of the eleven infants received a treosulfan dose of >39 g/sqm. Overall 342 
survival of infants was comparable to that of older age groups while EFS was even 343 
better, although statistical calculations have to be regarded with caution as the group 344 
of infants was small.  345 
Treosulfan has been used in combination with other drugs. Treosulfan and 346 
fludarabine were used in studies for adults with MDS or AML with good results with 347 
respect to toxicity.[46] However, our data show that the addition of a third drug, for 348 
example an alkylating agent such as thiotepa or melphalan, might be required for 349 
children as the combination of treosulfan with fludarabine alone was associated with 350 
significantly worse OS and a tendency for worse EFS in comparison to treosulfan, 351 
fludarabine and an alkylator. In patients with thalassemia, the combination of 352 
treosulfan with fludarabine and thiotepa was shown to be safe and effective.[26] In 353 
our cohort, this combination was also associated with low toxicity, low TRM (10%) 354 
and low rate of severe acute GvHD (6%) aside from good OS mentioned above. In 355 
terms of relapse and EFS, our multivariate analysis showed comparable results for 356 
the combination of treosulfan with cyclophosphamide or with fludarabine and 357 
melphalan/thiotepa (see table IV). 358 
Outcome for our whole cohort was acceptable with OS and EFS of 54 and 45%, 359 
respectively. In univariate analysis, patients undergoing HSCT without having 360 
reached CR (n=77) showed a trend for worse EFS and OS.  The lack of statistical 361 
significance regarding this point can be explained by a high percentage of patients 362 
with MDS/MPS in this group (n=33, 43%). As patients with MDS or MPS usually 363 
undergo primary HSCT without previous chemotherapy, patients with these 364 
diagnoses are per se not in remission at time of transplant.[8,9] Accordingly, not 365 
being in remission was associated worse EFS, OS and higher relapse rate with high 366 
significance in multivariate analysis emphasising the need to reduce leukemia and 367 
lymphoma burden before HSCT. [7,27] 368 
The optimal conditioning regimen for patients who need to undergo second or later 369 
transplantation is still debatable as the risk for toxic complications in these patients is 370 
high. Our data demonstrate that undergoing second or later HSCT in comparison to 371 
first HSCT did not significantly influence OS, EFS, TRM or relapse incidence (table III 372 
and IV). Treosulfan based conditioning seems to be an adequate and promising 373 
option for children in need of second transplantation in agreement with previous data 374 
in an adult cohort. [47]  375 
With increasing survival rates, late effects of HSCT become more relevant. Known 376 
long-term side effects of TBI include secondary malignancy, cataract, neurocognitive 377 
deficits and endocrine abnormalities including sterility. [43,48] Young children are 378 
especially prone to a high rate of late effects.[43] The risk of secondary malignancies 379 
is higher following TBI containing conditioning regimens compared to non-TBI, 380 
however also patients after busulfan-cyclophosphamide conditioning are at a higher 381 
risk of developing cancer compared to the normal population. [49,50] Although the 382 
rate of early toxicity following treosulfan is low, particularly mentionable in infants, 383 
little is known about long-term side effects as long-term studies following treosulfan-384 
based conditioning have not yet been published. Prospective studies are needed to 385 
investigate this matter. The international ALL SCTped 2012 FORUM protocol 386 
(EudraCT number 2012-003032-22) that has recently recruited the first patients 387 
compares outcome and toxicity of treosulfan- or busulfan-containing regimen versus 388 
TBI based conditioning in a prospective randomized study.  389 
 390 
Summary: 391 
Treosulfan based conditioning is a safe approach for children with malignant 392 
hematological disorders undergoing HSCT.  Even in high-risk patients such as infants 393 
or patients undergoing second or later HSCT, treosulfan was associated with low 394 
toxicity and good outcome. 395 
 396 
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Figure legends 564 
 565 
Figure 1: Early regimen related toxicity 566 
 567 
Figure 2: Outcome in relation to different variables: Overall (A) and event-free 568 
survival (B) were not dependent on different type of diagnosis. Patients without 569 
complete remission showed a tendency for worse event-free survival(C) while infant 570 
patients had significantly better outcome.(D) Addition of fludarabine alone and the 571 
group of other additional drugs were associated with significantly worse overall and 572 
event-free survival (E,F). 573 
 574 
Supplementary figure 1: Combination of conditioning drugs according to diagnosis. 575 
 576 
Supplementary table I: Patient characteristics are similar between the different 577 
types of diseases with regard to treosulfan dosing range, stem cell source and 578 
number of HSCT. 579 
Table I. Patient and HSCT procedure characteristics 
    
Number of patients 193 
Age Median 9.1 years (0.4-18.0);  
  <1 year, n= 11 (6%); 1-12 years, n=116 (60%); > 12 years, n=66 (34%) 
Sex Female, n= 83 (43%); male, = 110 (57%) 
Disease state CR1, n= 38 (20%); >CR1, n= 75 (39%); no CR, n= 77 (40%); NA, n=3 
Number of HSCT 1st, n= 142 (74%); >1st, n= 51 (26%) 
Donor type MFD, n= 53 (27%); MMFD, n= 28 (15%); UD, n= 112 (58%) 
Stem cell source BM, n= 97 (50%); PB, n= 72 (37%); CB, n= 23 (12%); BM+CB, n=1 
    
Preparative regimen according to treosulfan dose (g/sqm) 
Treosulfan <3x11 n= 18 (9%); +Cy, 7; +Flu, 8; +Flu/Mel 2;  +other, 1 
Treosulfan 3x11-<3x13 n=53 (27%); +Cy, 31; +Flu, 11; +Flu/Mel, 5; +Flu/Thio, 3; +other, 3 
Treosulfan 3x13-<3x15 n=117 (61%); +Cy, 10; +Flu, 20; +Flu/Mel, 18; +Flu/Thio, 59; +other, 10 
Treosulfan >3x15 n=5 (3%); +Flu 4, +Flu/Thio, 1 
    
GvHD prophylaxis CsA w/o MTX/MMF ± other, n=65 (34%)  
  CsA + MTX w/o MMF ± other,n=71 (37%) 
  CsA + MMF w/o MTX ± other, n=18 (9%) 
  other combinations, n=36 (19%); none n=3 
    
    
Abbreviations: HSCT=hematopoietic stem cell transplantation; CR= complete remission; NA=not 
available 
MFD= matched family donor; MMFD= mismatched family donor; UD= unrelated donor  
BM= bone marrow; PB= peripheral blood; CB= cord blood; Cy=cyclophosphamide; 
Flu= fludarabine; Mel= melphalan; Thio= thiotepa; CsA= ciclosporin A; MTX= methotrexate;  
MMF= mycophenolate mofetil; w/o= without 
 
Table 2. Early regimen related toxicity in correlation with diagnosis, treosulfan dose, age and number of HSCT             
  Diagnosis Treosulfan dose (g/sqm) number of HSCT age at HSCT (years) Combination of drugs    
    
   
  
    
  
 
  
   
  (treosulfan+) 
 
  
Toxicity ≥ grade 3 (%) ALL AML MPS/MDS other p <3x11  
3x11-
<3x13  >3x13  p first 
> 
first p 
0-
1 
1-
12 >12 p Cy Flu 
Flu+ 
Thio/Mel other p 
n= 71 57 40 25   18 53 122   142 51   11 116 66   48 43 88 14   
Stomatitis  26 31 26 40 0.54 24 42 24 0.27 29 28 0.84 20 27 33 0.57 30 31 24 50 0.25 
Diarrhea  17 22 13 16 0.71 28 19 14 0.19 17 18 0.896 27 19 12 0.31 19 17 15 29 0.64 
Vomiting  8 11 10 16 0.77 11 17 7 0.21 12 6 0.22 27 9 11 0.16 11 10 10 14 0.98 
Respiratory  10 16 10 12 0.79 0 15 13 0.33 11 18 0.20 18 14 9 0.53 11 10 14 21 0.66 
Bilirubin  10 9 15 16 0.66 6 11 13 0.5 11 14 0.53 9 9 17 0.25 10 24 6 14 0.03 
SGOT  19 30 33 36 0.24 28 30 26 0.71 26 32 0.38 9 21 41 0.006 31 40 21 14 0.09 
VOD (grade 1+2) 0 5 5 4 0.31 6 4 3 0.53 3 4 0.72 11 4 2 0.29 4 2 3 0 0.86 
Max. liver toxicity 25 32 40 36 0.38 28 36 30 0.82 29 38 0.24 18 25 44 0.02 38 47 22 21 0.02 
CNS  3 4 3 8 0.66 0 2 5 0.26 5 0 0.11 0 4 5 0.75 2 5 5 0 0.75 
PN  3 4 0 0 0.51 0 2 3 0.73 2 2 0.93 0 1 5 0.24 0 5 2 0 0.45 
Max. neurological 
toxicity 4 5 3 8 0.77 0 2 7 0.12 6 2 0.29 0 4 8 0.34 2 7 6 0 0.53 
                                            
Abbreviations: max= maximal, SGOT=serum glutamyl oxaloacetic transaminase, VOD= venoocclusive disease,  
      
  
CNS= central nervous system,  PN= peripheral neurological, Cy=cyclophosphamide, Flu=fludarabine, Thio=thiotepa, Mel=melphalan 
    
  
Chi-Square test was used for statistical analysis.                                 
 
Table III. Treatment related mortality (TRM) and disease related mortality (DRM) 
according to different variables 
  
    
  
  
 
TRM p DRM p 
Diagnosis           
ALL n=71 0.14±0.04 0.94 0.32±0.06 0.14 
AML n=57 0.13±0.05 
 
0.35±0.07   
MDS/MPS n=40 0.13±0.05 
 
0.18±0.06   
other leukemia n=25 0.16±0.07 
 
0.16±0.07   
Number of HSCT           
first n=142 0.11±0.03 0.20 0.27±0.04 0.68 
>first n=51 0.20±0.06 
 
0.30±0.07   
Status           
CR1 n=38 0.13±0.06 0.33 0.19±0.06 0.35 
>CR1 n=75 0.09±0.03 
 
0.32±0.05   
no CR n=77 0.18±0.04 
 
0.30±0.06   
Age           
0-1 year n=11 0.00±0.00 0.37 0.09±0.09 0.15 
1-12 years n=116 0.14±0.03 
 
0.33±0.05   
>12 years n=66 0.15±0.04   0.24±0.05   
Conditioning           
Cyclophosphamide n=48 0.10±0.04 0.36 0.15±0.05 0.02 
Flu+Thio n=63 0.10±0.14 
 
0.27±0.06   
Flu+Mel n=25 0.20±0.08 
 
0.24±0.09   
Flu n=43 0.19±0.06 
 
0.36±0.08   
other n=14 0.14±0.09   0.59±0.14   
Treosulfan dose           
<3x11 g/sqm n=18 0.06±0.05 0.46 0.34±0.11 0.48 
3x11-3x13 g/sqm n=53 0.11±0.04 
 
0.23±0.06   
>3x13 g/sqm n=122 0.16±0.03   0.29±0.04   
 
 Table IV. Multivariate analysis       
  
   
  
Diagnosis OS EFS TRM Relapse 
ALL 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
AML 0.85 (0.50-1.44); p=NS 0.71 (0.44-1.15); p=NS 0.85 (0.34-2.01); p=NS 0.68 (0.39-1.19); p=NS 
MDS/MPS 
0.35 (0.16-0.75); 
p=0.007 
0.30 (0.15-0.60); 
p=0.001 0.34 (0.11-1.04); p=0.06 
0.29 (0.12-0.67); 
p=0.004 
Other 0.46 (0.20-1.01); p=NS 
0.35 (0.16-0.74); 
p=0.006 0.50 (0.14-1.76); p=NS 
0.25 (0.10-0.64); 
p=0.004 
Number of HSCT   
 
    
first 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
>first 1.4 (0.83-2.4);p=NS 1.11 (0.69-1.80); p=NS 1.99 (0.83-4.79);p=NS 0.85 (0.48-1.51); p=NS 
CR status   
 
    
CR1 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
>CR1 0.78 (0.39-1.56); p=NS 0.98 (0.53-1.81); p=NS 0.39 (0.12-1-26); p=NS 1.43 (0.69-2.99); p=NS 
no CR 
2.18 (1.07-4.46); 
p=0.033 
2.81 (1.44-5.49); 
p=0.003 2.21 (0.71-6.90); p=NS 
3.49 (1.55-7.87); 
p=0.003 
Age   
 
    
1-12 years 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
0-1 year 0.20 (0.03-1.54); p=NS 
0.13 (0.02-0.98); 
p=0.048 NA 0.17 (0.02-1.29); p=NS 
>12 years 0.95 (0.58-1.56); p=NS 0.97 (0.62-1.53); p=NS 1.34 (0.62-2.92); p=NS 0.93 (0.55-1.57); p=NS 
Treosulfan dose   
 
    
>3x13 g/sqm 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
3x11-3x13 g/sqm 1.14 (0.59-2.21); p=NS 0.96 (0.52-1.74); p=NS 0.98 (0.32-3.02); p=NS 0.90 (0.45-1.82); p=NS 
< 3x11 g/sqm 0.68 (0.31-1.50); p=NS 0.72 (0.34-1.51); p=NS 0.44 (0.11-1.75); p=NS 1.01 (0.44-2.31); p=NS 
Conditioning   
 
    
Flu 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Cyclophosphamide 
0.47 (0.22-1.02); 
p=0.06 0.73 (0.38-1.43); p=NS 0.51 (0.15-1.72); p=NS 0.85 (0.39-1.84); p=NS 
Flu+ Thio/Mel 
0.61 (0.35-1.09); 
p=0.09 0.68 (0.40-1.15); p=NS 0.45 (0.18-1.09); p=NS 0.82 (0.43-1.56); p=NS 
Other 0.92 (0.41-2.06); p=NS 0.76 (0.34-1.67); p=NS 0.30 (0.06-1.51); p=NS 1.04 (0.42-2.58); p=NS 
Donor source   
 
    
MFD 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
MMFD 
3.66 (1.63-8.24); 
p=0.002 
2.12 (1.01-4.43); 
p=0.047 
7.12 (1.83-27.69); 
p=0.005 1.31 (0.54-3.17); p=NS 
UD  1.78 (0.99-3.20); 0.056 1.15 (0.69-1.92); p=NS 3.04 (1.11-8.29); p=0.03 0.84 (0.48-1.48); p=NS 
Stem cell source   
 
    
BM 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
PB 1.01 (0.57-1.78); p=NS 1.16 (0.68-1.98); p=NS 0.52 (0.20-1.36); p=NS 1.30 (0.69-2.44); p=NS 
CB 0.58 (0.21-1.60); p=NS 0.63 (0.26-1.52); p=NS 0.22 (0.03-1.78); p=NS 0.77 (0.29-2.04); p=NS 
Values are given as hazard ratio (95% CI). NS= not significant     
Abbreviations: OS= overall survival, EFS= event-free survival, TRM= treatment-related mortality, ALL= acute lymphoblastic   
leukemia, AML= acute myeloid leukemia, MDS= myelodysplastic syndrome, MPS= myeloproliferative syndrome,  
HSCT= hematopoietic stem cell transplantation, CR= complete remission, Flu= fludarabine, Thio= thiotepa, Mel= melphalan,   
MFD= matched family donor, MMFD= mismatched family donor, UD= unrelated donor, BM= bone marrow, PB= peripheral 
blood,  
CB= cord blood         
Supplemental table I. Patient characteristics according to diagnosis (%) 
    
ALL 
(n=71) 
AML 
(n=57) 
MDS/MPS 
(n=40) 
other 
(n=25) 
Age <1 year 10 0 10 0 
  1-12 ys 59 68 63 40 
  >12 ys 31 32 28 60 
Number of HSCT first 69 79 70 80 
  >first 31 21 30 20 
Status CR1 28 23 8 8 
  >CR1 58 44 3 32 
  no CR 14 33 89 60 
Donor MFD 34 24 12.5 40 
  MMFD 10 16 17.5 20 
  UD 56 60 70 40 
Stem cell source BM 54 49 40 60 
  PB 32 37 47.5 36 
  other 14 14 12.5 4 
Treosulfan dose <3x11 11 9 10 4 
  
3x11-
<3x13 30 24.5 33.5 20 
  
3x13-
<3x15 55 63 57.5 76 
  >3x15 4 3.5 0 0 
Conditioning regimen Cy 32 19 27.5 12 
(Treosulfan +) Flu 24 21 20 24 
  Flu+Mel 7 25 10 8 
  Flu+Thio 28 26 40 48 
  other 9 9 2.5 8 
Abbreviations: ALL=acute lymphoblastic leukemia, AML= acute myeloid 
leukemia 
MDS= myeloysplastic syndrome, MPS= myeloproliferative syndrome, ys=years  
HSCT= hematopoietic stem cell transplantation, CR= complete remission 
MFD= matched family donor, MMFD= mismatched family donor, UD=unrelated  
donor, BM=bone marow, PB=peripheral blood, Cy=cyclophosphamide, 
Flu= fludarabine, Mel= melphalan,Thio= thiotepa     
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